Carlsmed: COO promotion signals a scale-up, but the price already assumes it works

A spine-device startup promoting its head of operations to chief operating officer reads like boardroom housekeeping — the kind of item you scroll past. Today's announcement deserves a second look only because of what is happening around it. On September 8, Carlsmed (Nasdaq: CARL) named Jeff Bertolini, its senior vice president of operational excellence, as COO. The man moving up is a supply-chain and manufacturing veteran whose prior roles included operations and IT at SI-BONE and supply-chain leadership at NuVasive, not a salesman. That matters because the company's next problem is not whether surgeons want its product. It is whether Carlsmed can build and ship enough of them.

Carlsmed makes what it calls the aprevo platform: an AI-driven, personalized spinal implant — a custom device designed to a specific patient's anatomy. It is a different way of competing against the giant, off-the-shelf spine companies. And the numbers say demand is real. Second-quarter revenue rose 57% year over year to $18.9 million, and the company has now twice raised its full-year guidance, to $74–$78 million from roughly the $50.5 million it recorded in all of 2025. Trailing-twelve-month revenue is up about 65%. Gross margin expanded to 76.8% from 73.4% a year earlier — meaningful proof that the custom-manufacturing model can price profitably as volume grows.

Growth has outrun the company's own capacity to serve it

The CEO credits the company's proprietary digital production line with enabling scale "to meet strong market demand." That line is the clue to the promotion. A firm whose constraint is manufacturing capacity promotes its operations chief to the top operating seat when the product has proven itself and the fight moves to production, quality, and commercial reach. Bertolini's background is logistics-heavy: operations and supply chain at implant makers, then leading operational excellence at Carlsmed. Sending that person to the COO role is management saying the next phase is about output, not invention.

The demand side supports the timing. The trained-surgeon base grew more than 60% year over year, driven by early-career surgeons. A newer cervical product finished its second full quarter of commercialization and now accounts for roughly 10% of revenue — a second growth engine beside the core lumbar line. Then, days before the appointment, came the more important catalyst. The Centers for Medicare & Medicaid Services finalized three new MS-DRG codes for inpatient aprevo lumbar fusion procedures, effective October 1, 2026. Carlsmed's flagship procedure now has a permanent, favorable Medicare reimbursement path after years in which reimbursement uncertainty capped how aggressively hospitals would adopt a premium-priced personalized device.

The stock has already paid for the scale-up

None of this makes the promotion — or the growth — a reason to buy on its own, because the market is not waiting to be convinced. The shares are up roughly 23% this year and about 30% over the last four months, and they trade near $15.20 with a market value near $416 million. Against trailing revenue that is about 6.6 times sales — far richer than the roughly 3.2 times that profitable peer Globus Medical commands, and well above Alphatec's 1.7 times. For a company this unprofitable, the price is not resting on today's earnings (there are none); it is a bet that the growth keeps coming and eventually turns into cash.

That conversion is exactly where the case gets fragile. The business burns money at a heavy rate: free cash flow was negative roughly $35.7 million over the trailing twelve months, and the second-quarter net loss widened to $10.5 million from $6.8 million. Look at where the money goes and the tension shows. Sales and marketing alone ran to $11.9 million in the quarter — about 63 cents for every dollar of revenue. Add research and R&D and general costs, and total operating expenses hit $25.6 million against $14.5 million of gross profit. The company ended June with $89.3 million of cash and investments, so it is not in trouble tomorrow; at the current burn it has time. But growth is being bought with investor cash, not generated by the business yet.

That is the honest split between business quality and stock quality. A 57%-growing device franchise with expanding margins and a newly permanent reimbursement code is a strong company. The stock is a different question: at roughly 6.6 times trailing sales, with more than a dollar of operating cost for every dollar of revenue still crossing the income statement, the market is granting the business its full-scale future today rather than waiting to see it delivered. The promotion tells you the company thinks the hard part ahead is operational — which is the right thing to be worried about — but it does not reduce the price already paid.

The next two to four quarters are the falsifiable window. Watch whether gross margin keeps climbing as the cervical line scales, whether the Medicare codes that activate October 1 actually accelerate hospital adoption, and above all whether the net loss begins to narrow as a share of revenue — the first sign that the operating leverage this multiple implies is really arriving. Set against a fast-growing, well-financed medtech story, the appointment is a mild positive signal. It is worth more than a headline only because, for someone deciding whether to own the growth at this price, the scale-up that Bertolini now oversees is precisely what the valuation is asking the company to prove.